IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CAMPI, IRENE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.982
AS - Asia 3.898
NA - Nord America 3.832
SA - Sud America 507
AF - Africa 78
OC - Oceania 61
Continente sconosciuto - Info sul continente non disponibili 1
Totale 12.359
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.575
CN - Cina 1.144
SG - Singapore 983
IT - Italia 954
GB - Regno Unito 846
DE - Germania 420
SE - Svezia 346
BD - Bangladesh 331
VN - Vietnam 316
BR - Brasile 315
HK - Hong Kong 308
FR - Francia 241
RU - Federazione Russa 217
IN - India 205
NL - Olanda 190
CA - Canada 163
ES - Italia 125
TR - Turchia 117
JP - Giappone 107
IE - Irlanda 101
FI - Finlandia 99
KR - Corea 78
ID - Indonesia 77
UA - Ucraina 77
MX - Messico 69
DK - Danimarca 66
AU - Australia 55
CO - Colombia 50
BE - Belgio 45
CL - Cile 38
GR - Grecia 37
CH - Svizzera 35
PL - Polonia 35
EC - Ecuador 34
AR - Argentina 29
PE - Perù 29
TW - Taiwan 29
EU - Europa 26
PH - Filippine 24
IL - Israele 21
TH - Thailandia 21
CI - Costa d'Avorio 20
RO - Romania 20
AT - Austria 18
MY - Malesia 18
PT - Portogallo 17
CZ - Repubblica Ceca 16
HU - Ungheria 16
NO - Norvegia 16
PK - Pakistan 15
IQ - Iraq 14
IR - Iran 12
SA - Arabia Saudita 12
ZA - Sudafrica 10
EG - Egitto 9
MA - Marocco 9
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
DO - Repubblica Dominicana 7
DZ - Algeria 7
OM - Oman 7
TN - Tunisia 7
BG - Bulgaria 6
NZ - Nuova Zelanda 6
SY - Repubblica araba siriana 6
AZ - Azerbaigian 5
LB - Libano 5
LU - Lussemburgo 5
RS - Serbia 5
SI - Slovenia 5
UY - Uruguay 5
KZ - Kazakistan 4
LK - Sri Lanka 4
MT - Malta 4
SK - Slovacchia (Repubblica Slovacca) 4
VE - Venezuela 4
CR - Costa Rica 3
ET - Etiopia 3
HR - Croazia 3
JM - Giamaica 3
JO - Giordania 3
KE - Kenya 3
LT - Lituania 3
NI - Nicaragua 3
AL - Albania 2
AM - Armenia 2
GA - Gabon 2
GT - Guatemala 2
KW - Kuwait 2
LV - Lettonia 2
NG - Nigeria 2
NP - Nepal 2
PS - Palestinian Territory 2
QA - Qatar 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BM - Bermuda 1
Totale 12.365
Salva come PNG Salva come JPEG
Città #
Southend 668
Singapore 617
Ashburn 408
Milan 292
Chandler 282
Hong Kong 252
San Jose 232
Beijing 190
Dallas 144
Santa Clara 120
Los Angeles 119
Frankfurt am Main 113
Council Bluffs 106
Seattle 97
New York 96
Wilmington 96
Dublin 94
Princeton 92
Fairfield 90
Guangzhou 78
Ho Chi Minh City 77
Hanoi 74
Houston 69
Ann Arbor 68
Toronto 68
Bengaluru 57
Redwood City 56
Woodbridge 55
Lauterbourg 53
Helsinki 52
Shanghai 52
Jacksonville 51
Rome 51
Boardman 49
Buffalo 49
Jakarta 47
Nanjing 45
Cambridge 42
Munich 42
Dearborn 41
Moscow 41
Paris 41
Des Moines 40
Hefei 40
Tokyo 40
Istanbul 38
Jinan 34
Mountain View 34
São Paulo 34
Chicago 33
Redmond 32
Melbourne 31
Seoul 29
Bogotá 27
Columbus 27
Berlin 26
Hangzhou 26
Naples 26
Central 25
London 25
Madrid 25
Montreal 24
Shenyang 24
Athens 23
Lima 23
Changsha 22
Da Nang 22
Phoenix 22
Atlanta 20
Dong Ket 20
Nanchang 20
Santiago 20
The Dalles 20
Zhengzhou 20
Abidjan 19
Brussels 18
Washington 18
Barcelona 17
Denver 17
Essen 17
Falls Church 17
Sakarya 17
Taipei 17
Warsaw 17
Belo Horizonte 16
Bühl 16
Cangzhou 16
Somerville 16
Andover 15
Haiphong 15
New Delhi 15
Pillaro 15
Shenzhen 15
Bologna 14
Mainz 14
Mexico City 14
Turin 14
Amsterdam 13
Chengdu 13
Curitiba 13
Totale 6.646
Salva come PNG Salva come JPEG
Nome #
Prevention of orbitopathy by oral or intravenous steroid prophylaxis in short duration Graves’ disease patients undergoing radioiodine ablation : A prospective randomized control trial study 1.351
Efficacy profile and safety implications of very low dose Rituximab in patients with graves' orbitopathy 827
Quantification of global ocular motility impairment in graves' orbitopathy by measuring eye muscle ductions 735
Therapy of endocrine disease : Endocrine dilemma : management of Graves' orbitopathy 493
DESCRIZIONE DI UN CASO DI SEVERA INSULINO-RESISTENZA E LIPODISTROFIA PARZIALE, CAUSATO DA UNA MUTAZIONE A CARICO DEL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA (PPAR-GAMMA): CARATTERIZZAZIONE CLINICA E MOLECOLARE. 366
Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy. 345
Vitamin D and COVID-19 severity and related mortality : a prospective study in Italy 317
The relationship between liver histology and thyroid function tests in patients with nonalcoholic fatty liver disease (NAFLD) 298
B cell activating factor (BAFF) and BAFF receptor expression in autoimmune and nonautoimmune thyroid diseases 295
Syndromes of hormone resistance in the hypothalamic-pituitary-thyrod axis 283
Rituximab treatment in patients with active Graves' orbitopathy : effects on proinflammatory and humoral immune reactions 282
TBG deficiency: description of two novel mutations associated with complete TBG deficiency and review of the literature 278
Retinal photoreceptor functions are compromised in patients with resistance to thyroid hormone syndrome (RTHβ) 263
Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves' orbitopathy : a randomized controlled study 262
Increased cardiovascular morbidity and reduced life expectancy in a large Italian cohort of patients with resistance to thyroid hormone β (RTHβ) 254
Thyrotropin-secreting pituitary adenomas : outcome of pituitary surgery and irradiation 250
Fetal cell microchimerism : a protective role in autoimmune thyroid diseases 240
Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab : an open study 235
A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves' orbitopathy. 224
Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy 222
Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression 207
The Differential Diagnosis of Discrepant Thyroid Function Tests: Insistent Pitfalls and Updated Flow-Chart Based on a Long-Standing Experience 200
Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy 197
Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis 196
Analysis of a deiodinase 2 polymorphism (oRFa-Asp) in patients with Graves’ disease and controls : preliminary results 193
The spectrum of thyroid function tests during hospitalization for SARS COV-2 infection 193
Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy 189
Pituitary tumours : TSH-secreting adenomas 182
Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans 179
Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy 178
Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy : effects on orbital lymphocytic infiltrates 177
Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis 176
New immunomodulators in the treatment of Graves' ophthalmopathy 173
Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for graves' ophthalmopathy 170
Tissue sensitivity to thyroid hormones may change over time 170
The IGSF1 deficiency syndrome: characteristics of male and female patients 166
Severe Graves' Orbitopathy occurring in a patient with thyroid hemiagenesis 166
Impact of resistance to thyroid hormone on the cardiovascular system in adults 164
Pulsed intravenous methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodarone-induced thyrotoxicosis 161
Clinical consequences of variable results in the measurement of free thyroid hormones : unusual presentation of a family with a novel variant in the THRB gene causing resistance to thyroid hormone syndrome 155
Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement 154
A rare mutation of thyroid hormone receptor beta gene in thyroid hormone resistance syndrome 147
Resistance to Thyroid Hormone and Cardiovascular Risk 143
A novel albumin gene mutation (R222I) in familial dysalbuminemic hyperthyroxinemia 139
Syndromes of resistance to thyroid hormone action 127
Unusual causes of hyperthyrotropinemia and differential diagnosis of primary hypothyroidism: a revised diagnostic flowchart 126
Syndromes of Resistance to Thyroid Hormone Action 107
Syndromes of reduced sensitivity to thyroid hormones 102
Vitamin D, adiposity, and cardiometabolic risk: Insights from a multivariable cross-sectional study 86
Variation in Thyroid Hormone Metabolism May Affect COVID-19 Outcome 82
Thyroid hormone resistance: a novel mutation in thyroid hormone receptor beta (THRB) gene - case report 55
The therapeutic outcome of intravenous steroid therapy for active Graves{'} orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor 54
High-dose intravenous methylprednisolone is effective in subacute thyroiditis unresponsive to oral steroids 24
Challenging diagnosis of resistance to thyroid hormone in a patient with COVID-19, pituitary microadenoma and unusual response to octreotide long-acting release test 6
Association of COVID-19 mortality with serum selenium, zinc and copper: Six observational studies across Europe 5
null 3
Totale 12.772
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.801
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.801
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.202 88 83 55 99 97 68 110 81 154 88 86 193
2022/20231.282 145 163 94 100 113 190 46 94 137 55 68 77
2023/20241.104 62 73 77 104 195 80 60 80 64 82 95 132
2024/20252.231 107 206 67 177 213 96 148 233 144 266 251 323
2025/20264.100 366 263 368 306 350 250 519 184 325 264 504 401
2026/2027127 127 0 0 0 0 0 0 0 0 0 0 0
Totale 12.772